{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:33:56Z","timestamp":1778628836551,"version":"3.51.4"},"reference-count":224,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Genet Genomics"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00438-024-02206-6","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T02:49:14Z","timestamp":1733453354000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Beginning at the ends: telomere and telomere-based cancer therapeutics"],"prefix":"10.1007","volume":"300","author":[{"given":"Zahra","family":"Sadr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masoumeh","family":"Ghasemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soheyla","family":"Jafarpour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reyhaneh","family":"Seyfi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aida","family":"Ghasemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elham","family":"Boustanipour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0357-1573","authenticated-orcid":false,"given":"Hamid Reza Khorram","family":"Khorshid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1769-6329","authenticated-orcid":false,"given":"Naeim","family":"Ehtesham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"key":"2206_CR2","doi-asserted-by":"publisher","unstructured":"Agrawal S, Lin X et al (2024) Human replication protein A complex is a telomerase processivity factor essential for Telomere Maintenance. bioRxiv: the preprint server for biology: 2024.2008.2016.608355. https:\/\/doi.org\/10.1101\/2024.08.16.608355","DOI":"10.1101\/2024.08.16.608355"},{"issue":"1","key":"2206_CR3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12935-023-03041-2","volume":"23","author":"JH Ali","year":"2023","unstructured":"Ali JH, Walter M (2023) Combining old and new concepts in targeting telomerase for cancer therapy: transient, immediate, complete and combinatory attack (TICCA). Cancer Cell Int 23(1):197. https:\/\/doi.org\/10.1186\/s12935-023-03041-2","journal-title":"Cancer Cell Int"},{"key":"2206_CR4","doi-asserted-by":"publisher","first-page":"620776","DOI":"10.3389\/fvets.2020.620776","volume":"7","author":"G Altamura","year":"2020","unstructured":"Altamura G, Degli Uberti B et al (2020) The small molecule BIBR1532 exerts potential anti-cancer activities in preclinical models of feline oral squamous cell Carcinoma through Inhibition of Telomerase Activity and Down-Regulation of TERT. Front Vet Sci 7:620776. https:\/\/doi.org\/10.3389\/fvets.2020.620776","journal-title":"Front Vet Sci"},{"issue":"1","key":"2206_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/10409238.2016.1260090","volume":"52","author":"MS Apte","year":"2017","unstructured":"Apte MS, Cooper JP (2017) Life and cancer without telomerase: ALT and other strategies for making sure ends (don\u2019t) meet. Crit Rev Biochem Mol Biol 52(1):57\u201373. https:\/\/doi.org\/10.1080\/10409238.2016.1260090","journal-title":"Crit Rev Biochem Mol Biol"},{"issue":"2","key":"2206_CR6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3390\/biology11020185","volume":"11","author":"I Armend\u00e1riz-Castillo","year":"2022","unstructured":"Armend\u00e1riz-Castillo I, Hidalgo-Fern\u00e1ndez K et al (2022) Identification of key proteins from the Alternative Lengthening of telomeres-Associated Promyelocytic Leukemia Nuclear bodies Pathway. Biology 11(2):185","journal-title":"Biology"},{"issue":"1","key":"2206_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cell.2014.09.013","volume":"159","author":"N Arnoult","year":"2014","unstructured":"Arnoult N, Karlseder J (2014) ALT telomeres borrow from meiosis to get moving. Cell 159(1):11\u201312. https:\/\/doi.org\/10.1016\/j.cell.2014.09.013","journal-title":"Cell"},{"key":"2206_CR8","doi-asserted-by":"publisher","first-page":"111550","DOI":"10.1016\/j.biopha.2021.111550","volume":"139","author":"A Awadasseid","year":"2021","unstructured":"Awadasseid A, Ma X et al (2021) G-quadruplex stabilization via small-molecules as a potential anti-cancer strategy. Biomed Pharmacother 139:111550. https:\/\/doi.org\/10.1016\/j.biopha.2021.111550","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"2206_CR9","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1002\/med.21674","volume":"40","author":"S Bajaj","year":"2020","unstructured":"Bajaj S, Kumar MS et al (2020) Targeting telomerase for its advent in cancer therapeutics. Med Res Rev 40(5):1871\u20131919. https:\/\/doi.org\/10.1002\/med.21674","journal-title":"Med Res Rev"},{"key":"2206_CR10","doi-asserted-by":"publisher","unstructured":"Balon K, Sheriff A et al (2022) Targeting Cancer with CRISPR\/Cas9-Based therapy. Int J Mol Sci 23(1). https:\/\/doi.org\/10.3390\/ijms23010573","DOI":"10.3390\/ijms23010573"},{"issue":"3","key":"2206_CR11","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/ng.3781","volume":"49","author":"FP Barthel","year":"2017","unstructured":"Barthel FP, Wei W et al (2017) Systematic analysis of telomere length and somatic alterations in 31 cancer types. Nat Genet 49(3):349\u2013357. https:\/\/doi.org\/10.1038\/ng.3781","journal-title":"Nat Genet"},{"issue":"6238","key":"2206_CR12","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1126\/science.aab0015","volume":"348","author":"RJ Bell","year":"2015","unstructured":"Bell RJ, Rube HT et al (2015) Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Sci (New York NY) 348(6238):1036\u20131039. https:\/\/doi.org\/10.1126\/science.aab0015","journal-title":"Sci (New York NY)"},{"issue":"6","key":"2206_CR13","doi-asserted-by":"publisher","first-page":"458","DOI":"10.2174\/1568026620666200109114339","volume":"20","author":"J Berei","year":"2020","unstructured":"Berei J, Eckburg A et al (2020) Potential telomere-related pharmacological targets. Curr Top Med Chem 20(6):458\u2013484. https:\/\/doi.org\/10.2174\/1568026620666200109114339","journal-title":"Curr Top Med Chem"},{"issue":"1","key":"2206_CR14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12943-019-1100-5","volume":"18","author":"L Bian","year":"2019","unstructured":"Bian L, Meng Y et al (2019) MRE11-RAD50-NBS1 complex alterations and DNA damage response: implications for cancer treatment. Mol Cancer 18(1):169. https:\/\/doi.org\/10.1186\/s12943-019-1100-5","journal-title":"Mol Cancer"},{"issue":"10","key":"2206_CR15","doi-asserted-by":"publisher","first-page":"727","DOI":"10.18632\/aging.100206","volume":"2","author":"KB Blagoev","year":"2010","unstructured":"Blagoev KB, Goodwin EH et al (2010) Telomere sister chromatid exchange and the process of aging. Aging 2(10):727\u2013730. https:\/\/doi.org\/10.18632\/aging.100206","journal-title":"Aging"},{"issue":"5","key":"2206_CR16","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00412-012-0377-6","volume":"121","author":"N Bosco","year":"2012","unstructured":"Bosco N, de Lange T (2012) A TRF1-controlled common fragile site containing interstitial telomeric sequences. Chromosoma 121(5):465\u2013474. https:\/\/doi.org\/10.1007\/s00412-012-0377-6","journal-title":"Chromosoma"},{"key":"2206_CR1","doi-asserted-by":"crossref","unstructured":"Bruedigam C et al (2024) Imetelstat-mediatedalterations in fatty acid metabolism to induce ferroptosis as a therapeuticstrategy for acute myeloid leukemia. Nat Cancer 5(1):47\u201365","DOI":"10.1038\/s43018-023-00653-5"},{"key":"2206_CR17","doi-asserted-by":"publisher","unstructured":"Bryan TM (2020) G-Quadruplexes at telomeres: friend or foe? Molecules 25(16). https:\/\/doi.org\/10.3390\/molecules25163686","DOI":"10.3390\/molecules25163686"},{"key":"2206_CR18","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1038\/ncomms5198","volume":"5","author":"DV Bugreev","year":"2014","unstructured":"Bugreev DV, Huang F et al (2014) HOP2-MND1 modulates RAD51 binding to nucleotides and DNA. Nat Commun 5:4198. https:\/\/doi.org\/10.1038\/ncomms5198","journal-title":"Nat Commun"},{"issue":"1","key":"2206_CR20","doi-asserted-by":"publisher","first-page":"e85155","DOI":"10.1371\/journal.pone.0085155","volume":"9","author":"KM Burchett","year":"2014","unstructured":"Burchett KM, Yan Y et al (2014) Telomerase inhibitor Imetelstat (GRN163L) limits the lifespan of human pancreatic cancer cells. PLoS ONE 9(1):e85155. https:\/\/doi.org\/10.1371\/journal.pone.0085155","journal-title":"PLoS ONE"},{"issue":"48","key":"2206_CR19","doi-asserted-by":"publisher","first-page":"83754","DOI":"10.18632\/oncotarget.19410","volume":"8","author":"KM Burchett","year":"2017","unstructured":"Burchett KM, Etekpo A et al (2017) Inhibitors of telomerase and poly(ADP-ribose) polymerases synergize to limit the lifespan of pancreatic cancer cells. Oncotarget 8(48):83754\u201383767. https:\/\/doi.org\/10.18632\/oncotarget.19410","journal-title":"Oncotarget"},{"issue":"5","key":"2206_CR21","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1093\/nar\/gkv104","volume":"43","author":"FT Chang","year":"2015","unstructured":"Chang FT, Chan FL et al (2015) CHK1-driven histone H3.3 serine 31 phosphorylation is important for chromatin maintenance and cell survival in human ALT cancer cells. Nucleic Acids Res 43(5):2603\u20132614. https:\/\/doi.org\/10.1093\/nar\/gkv104","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"2206_CR25","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/nsmb.3498","volume":"24","author":"YA Chen","year":"2017","unstructured":"Chen YA, Shen YL et al (2017) Extrachromosomal telomere repeat DNA is linked to ALT development via cGAS-STING DNA sensing pathway. Nat Struct Mol Biol 24(12):1124\u20131131. https:\/\/doi.org\/10.1038\/nsmb.3498","journal-title":"Nat Struct Mol Biol"},{"issue":"8","key":"2206_CR22","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/cgt.2017.22","volume":"24","author":"P Chen","year":"2017","unstructured":"Chen P, Gu WL et al (2017) shRNA-mediated silencing of hTERT suppresses proliferation and promotes apoptosis in osteosarcoma cells. Cancer Gene Ther 24(8):325\u2013332. https:\/\/doi.org\/10.1038\/cgt.2017.22","journal-title":"Cancer Gene Ther"},{"issue":"21","key":"2206_CR24","doi-asserted-by":"publisher","first-page":"5369","DOI":"10.3390\/cancers13215369","volume":"13","author":"Y-Y Chen","year":"2021","unstructured":"Chen Y-Y, Dagg R et al (2021) The C-Circle Biomarker is secreted by alternative-lengthening-of-telomeres positive Cancer cells inside exosomes and provides a blood-based Diagnostic for ALT Activity. Cancers 13(21):5369","journal-title":"Cancers"},{"key":"2206_CR23","doi-asserted-by":"publisher","unstructured":"Chen X, Zhang T et al (2022) Mutant p53 in cancer: from molecular mechanism to therapeutic modulation. Cell Death Dis 13(11):974. https:\/\/doi.org\/10.1038\/s41419-022-05408-1","DOI":"10.1038\/s41419-022-05408-1"},{"issue":"4","key":"2206_CR26","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.jid.2017.11.021","volume":"138","author":"G Chhabra","year":"2018","unstructured":"Chhabra G, Wojdyla L et al (2018) Mechanism of action of G-Quadruplex-forming oligonucleotide homologous to the Telomere Overhang in Melanoma. J Invest Dermatol 138(4):903\u2013910. https:\/\/doi.org\/10.1016\/j.jid.2017.11.021","journal-title":"J Invest Dermatol"},{"issue":"2","key":"2206_CR27","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/annonc\/mdu550","volume":"26","author":"AA Chiappori","year":"2015","unstructured":"Chiappori AA, Kolevska T et al (2015) A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer. Ann Oncol 26(2):354\u2013362. https:\/\/doi.org\/10.1093\/annonc\/mdu550","journal-title":"Ann Oncol"},{"key":"2206_CR28","doi-asserted-by":"publisher","unstructured":"Clatterbuck Soper SF, Meltzer PS (2023) ATRX\/DAXX: guarding the genome against the hazards of ALT. Genes 14(4). https:\/\/doi.org\/10.3390\/genes14040790","DOI":"10.3390\/genes14040790"},{"key":"2206_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.gde.2020.01.002","volume":"60","author":"E Claude","year":"2020","unstructured":"Claude E, Decottignies A (2020) Telomere maintenance mechanisms in cancer: telomerase, ALT or lack thereof. Curr Opin Genet Dev 60:1\u20138. https:\/\/doi.org\/10.1016\/j.gde.2020.01.002","journal-title":"Curr Opin Genet Dev"},{"key":"2206_CR30","first-page":"1","volume-title":"Handbook of Chemical Biology of Nucleic acids","author":"SB Cohen","year":"2022","unstructured":"Cohen SB, Bryan TM (2022) Telomeres: structure and function. In: Sugimoto N (ed) Handbook of Chemical Biology of Nucleic acids. Springer Nature Singapore, Singapore, pp 1\u201317"},{"issue":"6","key":"2206_CR32","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1083\/jcb.201207189","volume":"199","author":"D Conomos","year":"2012","unstructured":"Conomos D, Stutz MD et al (2012) Variant repeats are interspersed throughout the telomeres and recruit nuclear receptors in ALT cells. J Cell Biol 199(6):893\u2013906. https:\/\/doi.org\/10.1083\/jcb.201207189","journal-title":"J Cell Biol"},{"issue":"9","key":"2206_CR31","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/nsmb.2877","volume":"21","author":"D Conomos","year":"2014","unstructured":"Conomos D, Reddel RR et al (2014) NuRD-ZNF827 recruitment to telomeres creates a molecular scaffold for homologous recombination. Nat Struct Mol Biol 21(9):760\u2013770. https:\/\/doi.org\/10.1038\/nsmb.2877","journal-title":"Nat Struct Mol Biol"},{"issue":"41","key":"2206_CR33","doi-asserted-by":"publisher","first-page":"6422","DOI":"10.2174\/1381612820666140630100702","volume":"20","author":"Z Crees","year":"2014","unstructured":"Crees Z, Girard J et al (2014) Oligonucleotides and G-quadruplex stabilizers: targeting telomeres and telomerase in cancer therapy. Curr Pharm Des 20(41):6422\u20136437. https:\/\/doi.org\/10.2174\/1381612820666140630100702","journal-title":"Curr Pharm Des"},{"key":"2206_CR34","doi-asserted-by":"publisher","unstructured":"De Vitis M, Berardinelli F et al (2018) Telomere length maintenance in Cancer: at the crossroad between Telomerase and Alternative Lengthening of telomeres (ALT). Int J Mol Sci 19(2). https:\/\/doi.org\/10.3390\/ijms19020606","DOI":"10.3390\/ijms19020606"},{"key":"2206_CR35","doi-asserted-by":"publisher","unstructured":"Deeg KI, Chung I et al (2016) Cancer cells with alternative lengthening of telomeres do not display a general hypersensitivity to ATR Inhibition. Frontiers in oncology 6. https:\/\/doi.org\/10.3389\/fonc.2016.00186","DOI":"10.3389\/fonc.2016.00186"},{"issue":"2","key":"2206_CR36","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.trecan.2015.07.007","volume":"1","author":"RL Dilley","year":"2015","unstructured":"Dilley RL, Greenberg RA (2015) ALTernative Telomere maintenance and Cancer. Trends cancer 1(2):145\u2013156. https:\/\/doi.org\/10.1016\/j.trecan.2015.07.007","journal-title":"Trends cancer"},{"issue":"22","key":"2206_CR37","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1182\/blood.V114.22.633.633","volume":"114","author":"JF DiPersio","year":"2009","unstructured":"DiPersio JF, Collins RH Jr et al (2009) Immune responses in AML patients following vaccination with GRNVAC1, autologous RNA transfected dendritic cells expressing telomerase Catalytic Subunit hTERT. Blood 114(22):633","journal-title":"Blood"},{"issue":"6","key":"2206_CR38","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.3390\/cancers13061213","volume":"13","author":"F Dogan","year":"2021","unstructured":"Dogan F, Forsyth NR (2021) Telomerase regulation: a role for epigenetics. Cancers 13(6):1213","journal-title":"Cancers"},{"key":"2206_CR39","doi-asserted-by":"publisher","unstructured":"Dosset M, Castro A et al (2020) Telomerase and CD4 T cell immunity in Cancer. Cancers 12(6). https:\/\/doi.org\/10.3390\/cancers12061687","DOI":"10.3390\/cancers12061687"},{"issue":"37","key":"2206_CR40","doi-asserted-by":"publisher","first-page":"15726","DOI":"10.1073\/pnas.0907689106","volume":"106","author":"I Draskovic","year":"2009","unstructured":"Draskovic I, Arnoult N et al (2009) Probing PML body function in ALT cells reveals spatiotemporal requirements for telomere recombination. Proc Natl Acad Sci USA 106(37):15726\u201315731. https:\/\/doi.org\/10.1073\/pnas.0907689106","journal-title":"Proc Natl Acad Sci USA"},{"key":"2206_CR41","doi-asserted-by":"publisher","first-page":"589929","DOI":"10.3389\/fimmu.2020.589929","volume":"11","author":"M Dratwa","year":"2020","unstructured":"Dratwa M, Wysocza\u0144ska B et al (2020) TERT\u2014regulation and roles in cancer formation. Front Immunol 11:589929","journal-title":"Front Immunol"},{"issue":"3","key":"2206_CR42","doi-asserted-by":"publisher","first-page":"zcaa022","DOI":"10.1093\/narcan\/zcaa022","volume":"2","author":"R Dueva","year":"2020","unstructured":"Dueva R, Iliakis G (2020) Replication protein A: a multifunctional protein with roles in DNA replication, repair and beyond. NAR cancer 2(3):zcaa022. https:\/\/doi.org\/10.1093\/narcan\/zcaa022","journal-title":"NAR cancer"},{"key":"2206_CR43","doi-asserted-by":"publisher","unstructured":"Eckburg A, Dein J et al (2020) Oligonucleotides and microRNAs targeting telomerase subunits in Cancer Therapy. Cancers 12(9). https:\/\/doi.org\/10.3390\/cancers12092337","DOI":"10.3390\/cancers12092337"},{"key":"2206_CR44","doi-asserted-by":"crossref","unstructured":"Eitsuka T, Nakagawa K et al (2018) Modulation of telomerase activity in Cancer cells by Dietary compounds. A ReviewInternational journal of molecular sciences","DOI":"10.3390\/ijms19020478"},{"issue":"19","key":"2206_CR45","doi-asserted-by":"publisher","first-page":"10395","DOI":"10.1093\/nar\/gkad764","volume":"51","author":"R El-Khoury","year":"2023","unstructured":"El-Khoury R, Roman M et al (2023) Telomeric i-motifs and C-strands inhibit parallel G-quadruplex extension by telomerase. Nucleic Acids Res 51(19):10395\u201310410","journal-title":"Nucleic Acids Res"},{"key":"2206_CR46","doi-asserted-by":"publisher","first-page":"682492","DOI":"10.3389\/fimmu.2021.682492","volume":"12","author":"EB Ellingsen","year":"2021","unstructured":"Ellingsen EB, Mangsbo SM et al (2021) Telomerase as a target for therapeutic Cancer vaccines and considerations for optimizing their clinical potential. Front Immunol 12:682492. https:\/\/doi.org\/10.3389\/fimmu.2021.682492","journal-title":"Front Immunol"},{"issue":"7","key":"2206_CR47","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1093\/nar\/gku114","volume":"42","author":"H Episkopou","year":"2014","unstructured":"Episkopou H, Draskovic I et al (2014) Alternative lengthening of telomeres is characterized by reduced compaction of telomeric chromatin. Nucleic Acids Res 42(7):4391\u20134405. https:\/\/doi.org\/10.1093\/nar\/gku114","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"2206_CR48","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3892\/ijo.2017.4043","volume":"51","author":"X Fang","year":"2017","unstructured":"Fang X, Hu T et al (2017) Differences in telomerase activity and the effects of AZT in aneuploid and euploid cells in colon cancer. Int J Oncol 51(2):525\u2013532. https:\/\/doi.org\/10.3892\/ijo.2017.4043","journal-title":"Int J Oncol"},{"key":"2206_CR49","doi-asserted-by":"publisher","unstructured":"Farooqi AA, Mansoor Q et al (2018) MicroRNA Regulation of Telomerase Reverse Transcriptase (TERT): Micro machines pull Strings of Papier-M\u00e2ch\u00e9 Puppets. Int J Mol Sci 19(4). https:\/\/doi.org\/10.3390\/ijms19041051","DOI":"10.3390\/ijms19041051"},{"issue":"6","key":"2206_CR51","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s00262-013-1415-9","volume":"62","author":"D Fenoglio","year":"2013","unstructured":"Fenoglio D, Traverso P et al (2013) A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer. Cancer Immunol Immunother 62(6):1041\u20131052. https:\/\/doi.org\/10.1007\/s00262-013-1415-9","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"2206_CR50","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1080\/21645515.2015.1012032","volume":"11","author":"D Fenoglio","year":"2015","unstructured":"Fenoglio D, Parodi A et al (2015) Immunogenicity of GX301 cancer vaccine: four (telomerase peptides) are better than one. Hum Vaccin Immunother 11(4):838\u2013850. https:\/\/doi.org\/10.1080\/21645515.2015.1012032","journal-title":"Hum Vaccin Immunother"},{"issue":"7339","key":"2206_CR52","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/nature09772","volume":"471","author":"RL Flynn","year":"2011","unstructured":"Flynn RL, Centore RC et al (2011) TERRA and hnRNPA1 orchestrate an RPA-to-POT1 switch on telomeric single-stranded DNA. Nature 471(7339):532\u2013536. https:\/\/doi.org\/10.1038\/nature09772","journal-title":"Nature"},{"issue":"6219","key":"2206_CR53","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1126\/science.1257216","volume":"347","author":"RL Flynn","year":"2015","unstructured":"Flynn RL, Cox KE et al (2015) Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Sci (New York NY) 347(6219):273\u2013277. https:\/\/doi.org\/10.1126\/science.1257216","journal-title":"Sci (New York NY)"},{"issue":"11","key":"2206_CR54","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/nar\/gkac113","volume":"50","author":"L Frank","year":"2022","unstructured":"Frank L, Rademacher A et al (2022) ALT-FISH quantifies alternative lengthening of telomeres activity by imaging of single-stranded repeats. Nucleic Acids Res 50(11):e61\u2013e61. https:\/\/doi.org\/10.1093\/nar\/gkac113","journal-title":"Nucleic Acids Res"},{"issue":"22","key":"2206_CR55","doi-asserted-by":"publisher","first-page":"31639","DOI":"10.18632\/oncotarget.9335","volume":"7","author":"RE Frink","year":"2016","unstructured":"Frink RE, Peyton M et al (2016) Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner. Oncotarget 7(22):31639\u201331651. https:\/\/doi.org\/10.18632\/oncotarget.9335","journal-title":"Oncotarget"},{"issue":"11","key":"2206_CR56","doi-asserted-by":"publisher","first-page":"6472","DOI":"10.1093\/nar\/gkae389","volume":"52","author":"VM Gaela","year":"2024","unstructured":"Gaela VM, Hsia H-Y et al (2024) Orphan nuclear receptors-induced ALT-associated PML bodies are targets for ALT inhibition. Nucleic Acids Res 52(11):6472\u20136489. https:\/\/doi.org\/10.1093\/nar\/gkae389","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"2206_CR57","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.jcyt.2018.09.007","volume":"20","author":"D Galati","year":"2018","unstructured":"Galati D, Zanotta S (2018) Empowering dendritic cell cancer vaccination: the role of combinatorial strategies. Cytotherapy 20(11):1309\u20131323. https:\/\/doi.org\/10.1016\/j.jcyt.2018.09.007","journal-title":"Cytotherapy"},{"issue":"9","key":"2206_CR58","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41568-022-00490-1","volume":"22","author":"J Gao","year":"2022","unstructured":"Gao J, Pickett HA (2022) Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies. Nat Rev Cancer 22(9):515\u2013532. https:\/\/doi.org\/10.1038\/s41568-022-00490-1","journal-title":"Nat Rev Cancer"},{"issue":"23","key":"2206_CR59","doi-asserted-by":"publisher","first-page":"e104500","DOI":"10.15252\/embj.2020104500","volume":"39","author":"G Glousker","year":"2020","unstructured":"Glousker G, Briod AS et al (2020) Human shelterin protein POT1 prevents severe telomere instability induced by homology-directed DNA repair. EMBO J 39(23):e104500. https:\/\/doi.org\/10.15252\/embj.2020104500","journal-title":"EMBO J"},{"issue":"1","key":"2206_CR60","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ajpath.2012.10.001","volume":"182","author":"AR Gocha","year":"2013","unstructured":"Gocha AR, Nuovo G et al (2013) Human sarcomas are mosaic for telomerase-dependent and telomerase-independent telomere maintenance mechanisms: implications for telomere-based therapies. Am J Pathol 182(1):41\u201348. https:\/\/doi.org\/10.1016\/j.ajpath.2012.10.001","journal-title":"Am J Pathol"},{"issue":"22","key":"2206_CR61","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.2174\/1568026616666160212122425","volume":"16","author":"DL Gomez","year":"2016","unstructured":"Gomez DL, Armando RG et al (2016) Telomerase as a Cancer Target. Development of New molecules. Curr Top Med Chem 16(22):2432\u20132440. https:\/\/doi.org\/10.2174\/1568026616666160212122425","journal-title":"Curr Top Med Chem"},{"issue":"1","key":"2206_CR62","doi-asserted-by":"publisher","first-page":"5033","DOI":"10.1038\/s41467-022-32680-8","volume":"13","author":"N Gulve","year":"2022","unstructured":"Gulve N, Su C et al (2022) DAXX-ATRX regulation of p53 chromatin binding and DNA damage response. Nat Commun 13(1):5033. https:\/\/doi.org\/10.1038\/s41467-022-32680-8","journal-title":"Nat Commun"},{"key":"2206_CR63","doi-asserted-by":"publisher","unstructured":"Guo Y, Chen Y et al (2022) TERT promoter mutations and telomerase in Melanoma. J Oncol 2022(6300329). https:\/\/doi.org\/10.1155\/2022\/6300329","DOI":"10.1155\/2022\/6300329"},{"issue":"17","key":"2206_CR64","doi-asserted-by":"publisher","first-page":"13244","DOI":"10.18632\/oncotarget.24284","volume":"9","author":"H Guzman","year":"2018","unstructured":"Guzman H, Sanders K et al (2018) miR-128 inhibits telomerase activity by targeting TERT mRNA. Oncotarget 9(17):13244\u201313253. https:\/\/doi.org\/10.18632\/oncotarget.24284","journal-title":"Oncotarget"},{"issue":"6041","key":"2206_CR65","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1126\/science.1207313","volume":"333","author":"CM Heaphy","year":"2011","unstructured":"Heaphy CM, de Wilde RF et al (2011) Altered telomeres in tumors with ATRX and DAXX mutations. Sci (New York NY) 333(6041):425. https:\/\/doi.org\/10.1126\/science.1207313","journal-title":"Sci (New York NY)"},{"key":"2206_CR66","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.gde.2013.11.005","volume":"24","author":"B Heidenreich","year":"2014","unstructured":"Heidenreich B, Rachakonda PS et al (2014) TERT promoter mutations in cancer development. Curr Opin Genet Dev 24:30\u201337. https:\/\/doi.org\/10.1016\/j.gde.2013.11.005","journal-title":"Curr Opin Genet Dev"},{"issue":"4","key":"2206_CR67","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.3892\/ijo.2014.2557","volume":"45","author":"K Higashi","year":"2014","unstructured":"Higashi K, Hazama S et al (2014) A novel cancer vaccine strategy with combined IL-18 and HSV-TK gene therapy driven by the hTERT promoter in a murine colorectal cancer model. Int J Oncol 45(4):1412\u20131420. https:\/\/doi.org\/10.3892\/ijo.2014.2557","journal-title":"Int J Oncol"},{"issue":"3","key":"2206_CR68","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.trecan.2019.12.009","volume":"6","author":"SM Hoang","year":"2020","unstructured":"Hoang SM, O\u2019Sullivan RJ (2020) Alternative lengthening of telomeres: Building bridges to connect chromosome ends. Trends cancer 6(3):247\u2013260. https:\/\/doi.org\/10.1016\/j.trecan.2019.12.009","journal-title":"Trends cancer"},{"key":"2206_CR69","doi-asserted-by":"publisher","unstructured":"Hong J, Yun CO (2019) Telomere Gene Therapy: polarizing therapeutic goals for treatment of various diseases. Cells 8(5). https:\/\/doi.org\/10.3390\/cells8050392","DOI":"10.3390\/cells8050392"},{"issue":"4","key":"2206_CR73","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.cell.2011.12.028","volume":"148","author":"J Hu","year":"2012","unstructured":"Hu J, Hwang SS et al (2012) Antitelomerase therapy provokes ALT and mitochondrial adaptive mechanisms in cancer. Cell 148(4):651\u2013663. https:\/\/doi.org\/10.1016\/j.cell.2011.12.028","journal-title":"Cell"},{"key":"2206_CR71","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1182\/blood-2019-126189","volume":"134","author":"CS Hu","year":"2019","unstructured":"Hu CS, Huang F et al (2019) Combination treatment with imetelstat, a telomerase inhibitor, and ruxolitinib depletes myelofibrosis hematopoietic stem cells and progenitor cells. Blood 134:2963","journal-title":"Blood"},{"issue":"1","key":"2206_CR70","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","volume":"5","author":"B Hu","year":"2020","unstructured":"Hu B, Zhong L et al (2020) Therapeutic siRNA: state of the art. Signal Transduct Target Ther 5(1):101. https:\/\/doi.org\/10.1038\/s41392-020-0207-x","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"2206_CR72","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1042\/bst20230300","volume":"52","author":"H Hu","year":"2024","unstructured":"Hu H, Yan HL et al (2024) Structural biology of shelterin and telomeric chromatin: the pieces and an unfinished puzzle. Biochem Soc Trans 52(4):1551\u20131564. https:\/\/doi.org\/10.1042\/bst20230300","journal-title":"Biochem Soc Trans"},{"issue":"9","key":"2206_CR75","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1039\/C7MB00354D","volume":"13","author":"X Huang","year":"2017","unstructured":"Huang X, Zhuang C et al (2017) An enhanced hTERT promoter-driven CRISPR\/Cas9 system selectively inhibits the progression of bladder cancer cells. Mol Biosyst 13(9):1713\u20131721. https:\/\/doi.org\/10.1039\/C7MB00354D","journal-title":"Mol Biosyst"},{"issue":"1","key":"2206_CR74","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1186\/s12935-021-02405-w","volume":"21","author":"G Huang","year":"2021","unstructured":"Huang G, Chen J et al (2021) Epigenetic modification and BRAF gene mutation in thyroid carcinoma. Cancer Cell Int 21(1):687. https:\/\/doi.org\/10.1186\/s12935-021-02405-w","journal-title":"Cancer Cell Int"},{"issue":"1","key":"2206_CR76","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13073-016-0324-x","volume":"8","author":"MA Jafri","year":"2016","unstructured":"Jafri MA, Ansari SA et al (2016) Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies. Genome Med 8(1):69. https:\/\/doi.org\/10.1186\/s13073-016-0324-x","journal-title":"Genome Med"},{"key":"2206_CR77","doi-asserted-by":"crossref","unstructured":"Jenner LP, Peska V et al (2022) Telomeres and Their NeighborsGenes","DOI":"10.3390\/genes13091663"},{"issue":"7","key":"2206_CR79","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1128\/mcb.25.7.2708-2721.2005","volume":"25","author":"WQ Jiang","year":"2005","unstructured":"Jiang WQ, Zhong ZH et al (2005) Suppression of alternative lengthening of telomeres by Sp100-mediated sequestration of the MRE11\/RAD50\/NBS1 complex. Mol Cell Biol 25(7):2708\u20132721. https:\/\/doi.org\/10.1128\/mcb.25.7.2708-2721.2005","journal-title":"Mol Cell Biol"},{"issue":"9","key":"2206_CR78","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1016\/j.molcel.2024.03.011","volume":"84","author":"H Jiang","year":"2024","unstructured":"Jiang H, Zhang T et al (2024) BLM helicase unwinds lagging strand substrates to assemble the ALT telomere damage response. Mol Cell 84(9):1684\u20131698e1689. https:\/\/doi.org\/10.1016\/j.molcel.2024.03.011","journal-title":"Mol Cell"},{"issue":"29","key":"2206_CR80","doi-asserted-by":"publisher","first-page":"e11548","DOI":"10.1097\/md.0000000000011548","volume":"97","author":"A Jin","year":"2018","unstructured":"Jin A, Xu J et al (2018) The role of TERT promoter mutations in postoperative and preoperative diagnosis and prognosis in thyroid cancer. Med (Baltim) 97(29):e11548. https:\/\/doi.org\/10.1097\/md.0000000000011548","journal-title":"Med (Baltim)"},{"issue":"1","key":"2206_CR81","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41416-023-02474-w","volume":"130","author":"JH Jo","year":"2024","unstructured":"Jo JH, Kim YT et al (2024) Efficacy of GV1001 with gemcitabine\/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4\/2015): an open-label, randomised, phase 3 trial. Br J Cancer 130(1):43\u201352. https:\/\/doi.org\/10.1038\/s41416-023-02474-w","journal-title":"Br J Cancer"},{"issue":"22","key":"2206_CR82","doi-asserted-by":"publisher","first-page":"9494","DOI":"10.1158\/0008-5472.Can-10-0233","volume":"70","author":"I Joseph","year":"2010","unstructured":"Joseph I, Tressler R et al (2010) The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines. Cancer Res 70(22):9494\u20139504. https:\/\/doi.org\/10.1158\/0008-5472.Can-10-0233","journal-title":"Cancer Res"},{"issue":"43","key":"2206_CR83","doi-asserted-by":"publisher","first-page":"5768","DOI":"10.1016\/j.vaccine.2017.09.011","volume":"35","author":"C Kailashiya","year":"2017","unstructured":"Kailashiya C, Sharma HB et al (2017) Telomerase based anticancer immunotherapy and vaccines approaches. Vaccine 35(43):5768\u20135775. https:\/\/doi.org\/10.1016\/j.vaccine.2017.09.011","journal-title":"Vaccine"},{"issue":"7","key":"2206_CR84","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00432-024-05867-3","volume":"150","author":"A Kallingal","year":"2024","unstructured":"Kallingal A, Krzemieniecki R et al (2024) TRF1 and TRF2: pioneering targets in telomere-based cancer therapy. J Cancer Res Clin Oncol 150(7):353. https:\/\/doi.org\/10.1007\/s00432-024-05867-3","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"2206_CR85","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/embor.2011.227","volume":"13","author":"Z Kaul","year":"2011","unstructured":"Kaul Z, Cesare AJ et al (2011) Five dysfunctional telomeres predict onset of senescence in human cells. EMBO Rep 13(1):52\u201359. https:\/\/doi.org\/10.1038\/embor.2011.227","journal-title":"EMBO Rep"},{"issue":"4","key":"2206_CR86","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.bbrc.2010.07.117","volume":"399","author":"CV Kavitha","year":"2010","unstructured":"Kavitha CV, Choudhary B et al (2010) Differential regulation of MRN (Mre11\u2013Rad50\u2013Nbs1) complex subunits and telomerase activity in cancer cells. Biochem Biophys Res Commun 399(4):575\u2013580. https:\/\/doi.org\/10.1016\/j.bbrc.2010.07.117","journal-title":"Biochem Biophys Res Commun"},{"key":"2206_CR87","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.3389\/fonc.2019.01518","volume":"9","author":"T Kent","year":"2019","unstructured":"Kent T, Gracias D et al (2019) Alternative lengthening of telomeres in Pediatric Cancer: mechanisms to therapies. Front Oncol 9:1518. https:\/\/doi.org\/10.3389\/fonc.2019.01518","journal-title":"Front Oncol"},{"issue":"3","key":"2206_CR88","doi-asserted-by":"publisher","first-page":"142","DOI":"10.22034\/ibj.22.3.142","volume":"22","author":"F Khatami","year":"2018","unstructured":"Khatami F, Tavangar SM (2018) Genetic and epigenetic of medullary thyroid Cancer. Iran Biomed J 22(3):142\u2013150. https:\/\/doi.org\/10.22034\/ibj.22.3.142","journal-title":"Iran Biomed J"},{"key":"2206_CR89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcell.2017.00001","volume":"5","author":"E Khattar","year":"2017","unstructured":"Khattar E, Tergaonkar V (2017) Transcriptional regulation of telomerase reverse transcriptase (TERT) by MYC. Front cell Dev Biology 5:1","journal-title":"Front cell Dev Biology"},{"issue":"21","key":"2206_CR90","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1182\/blood.V116.21.2190.2190","volume":"116","author":"HJ Khoury","year":"2010","unstructured":"Khoury HJ, Collins RH Jr et al (2010) Prolonged administration of the telomerase vaccine GRNVAC1 is well tolerated and appears to be associated with favorable outcomes in high-risk acute myeloid leukemia (AML). Blood 116(21):2190","journal-title":"Blood"},{"key":"2206_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.diff.2017.11.005","volume":"99","author":"W Kim","year":"2018","unstructured":"Kim W, Shay JW (2018) Long-range telomere regulation of gene expression: Telomere looping and telomere position effect over long distances (TPE-OLD). Differ Res Biol Divers 99:1\u20139. https:\/\/doi.org\/10.1016\/j.diff.2017.11.005","journal-title":"Differ Res Biol Divers"},{"issue":"15","key":"2206_CR91","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1089\/104303403769211637","volume":"14","author":"E Kim","year":"2003","unstructured":"Kim E, Kim JH et al (2003) Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum Gene Ther 14(15):1415\u20131428. https:\/\/doi.org\/10.1089\/104303403769211637","journal-title":"Hum Gene Ther"},{"key":"2206_CR92","doi-asserted-by":"publisher","first-page":"101546","DOI":"10.1016\/j.tranon.2022.101546","volume":"26","author":"JH Kim","year":"2022","unstructured":"Kim JH, Cho Y-R et al (2022) A novel telomerase-derived peptide GV1001-mediated inhibition of angiogenesis: regulation of VEGF\/VEGFR-2 signaling pathways. Translational Oncol 26:101546. https:\/\/doi.org\/10.1016\/j.tranon.2022.101546","journal-title":"Translational Oncol"},{"key":"2206_CR93","doi-asserted-by":"publisher","unstructured":"Kim MJ, Kim JK et al (2022a) TERT promoter and BRAF V600E mutations in papillary thyroid Cancer: a single-Institution experience in Korea. Cancers 14(19). https:\/\/doi.org\/10.3390\/cancers14194928","DOI":"10.3390\/cancers14194928"},{"issue":"4","key":"2206_CR94","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.7150\/jca.70385","volume":"13","author":"S Kim","year":"2022","unstructured":"Kim S, Kim BJ et al (2022b) A phase II study of chemotherapy in combination with telomerase peptide vaccine (GV1001) as second-line treatment in patients with metastatic colorectal cancer. J Cancer 13(4):1363\u20131369. https:\/\/doi.org\/10.7150\/jca.70385","journal-title":"J Cancer"},{"issue":"5","key":"2206_CR96","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1172\/JCI79134","volume":"125","author":"CM Koh","year":"2015","unstructured":"Koh CM, Khattar E et al (2015) Telomerase regulates MYC-driven oncogenesis independent of its reverse transcriptase activity. J Clin Investig 125(5):2109\u20132122","journal-title":"J Clin Investig"},{"issue":"4","key":"2206_CR97","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1093\/nar\/gkv091","volume":"43","author":"M Komosa","year":"2015","unstructured":"Komosa M, Root H et al (2015) Visualization and quantitative analysis of extrachromosomal telomere-repeat DNA in individual human cells by Halo-FISH. Nucleic Acids Res 43(4):2152\u20132163. https:\/\/doi.org\/10.1093\/nar\/gkv091","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"2206_CR98","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s10549-015-3270-1","volume":"149","author":"JE Koziel","year":"2015","unstructured":"Koziel JE, Herbert BS (2015) The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2\u2009+\u2009breast cancer cells. Breast Cancer Res Treat 149(3):607\u2013618. https:\/\/doi.org\/10.1007\/s10549-015-3270-1","journal-title":"Breast Cancer Res Treat"},{"issue":"15","key":"2206_CR99","doi-asserted-by":"publisher","first-page":"4232","DOI":"10.1016\/j.jmb.2020.02.004","volume":"432","author":"M Lalonde","year":"2020","unstructured":"Lalonde M, Chartrand P (2020) TERRA, a Multifaceted Regulator of Telomerase Activity at Telomeres. J Mol Biol 432(15):4232\u20134243. https:\/\/doi.org\/10.1016\/j.jmb.2020.02.004","journal-title":"J Mol Biol"},{"issue":"17","key":"2206_CR100","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.1016\/j.febslet.2010.07.029","volume":"584","author":"BJ Lamarche","year":"2010","unstructured":"Lamarche BJ, Orazio NI et al (2010) The MRN complex in double-strand break repair and telomere maintenance. FEBS Lett 584(17):3682\u20133695. https:\/\/doi.org\/10.1016\/j.febslet.2010.07.029","journal-title":"FEBS Lett"},{"issue":"1","key":"2206_CR101","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12885-019-5424-8","volume":"19","author":"RT Lawlor","year":"2019","unstructured":"Lawlor RT, Veronese N et al (2019) Alternative lengthening of telomeres (ALT) influences survival in soft tissue sarcomas: a systematic review with meta-analysis. BMC Cancer 19(1):232. https:\/\/doi.org\/10.1186\/s12885-019-5424-8","journal-title":"BMC Cancer"},{"key":"2206_CR102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-018-0422-8","volume":"25","author":"R Le\u00e3o","year":"2018","unstructured":"Le\u00e3o R, Apol\u00f3nio JD et al (2018) Mechanisms of human telomerase reverse transcriptase (h TERT) regulation: clinical impacts in cancer. J Biomed Sci 25:1\u201312","journal-title":"J Biomed Sci"},{"key":"2206_CR103","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3389\/fgene.2016.00083","volume":"7","author":"KA Lewis","year":"2016","unstructured":"Lewis KA, Tollefsbol TO (2016) Regulation of the telomerase reverse transcriptase subunit through epigenetic mechanisms. Front Genet 7:83","journal-title":"Front Genet"},{"issue":"6","key":"2206_CR106","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1158\/0008-5472.Can-13-3568","volume":"74","author":"Y Li","year":"2014","unstructured":"Li Y, Tergaonkar V (2014) Noncanonical functions of telomerase: implications in telomerase-targeted cancer therapies. Cancer Res 74(6):1639\u20131644. https:\/\/doi.org\/10.1158\/0008-5472.Can-13-3568","journal-title":"Cancer Res"},{"issue":"4","key":"2206_CR104","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1089\/cbr.2010.0908","volume":"26","author":"W Li","year":"2011","unstructured":"Li W, Tan J et al (2011) Cotransfected sodium iodide symporter and human tyroperoxidase genes following human telomerase reverse transcriptase promoter for targeted radioiodine therapy of malignant glioma cells. Cancer Biother Radiopharm 26(4):443\u2013451. https:\/\/doi.org\/10.1089\/cbr.2010.0908","journal-title":"Cancer Biother Radiopharm"},{"issue":"2","key":"2206_CR105","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/ijc.31060","volume":"142","author":"Y Li","year":"2018","unstructured":"Li Y, Hong J et al (2018) Potent antitumor effect of tumor microenvironment-targeted oncolytic adenovirus against desmoplastic pancreatic cancer. Int J Cancer 142(2):392\u2013413. https:\/\/doi.org\/10.1002\/ijc.31060","journal-title":"Int J Cancer"},{"issue":"4","key":"2206_CR107","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41580-021-00328-y","volume":"22","author":"CJ Lim","year":"2021","unstructured":"Lim CJ, Cech TR (2021) Shaping human telomeres: from shelterin and CST complexes to telomeric chromatin organization. Nat Rev Mol Cell Biol 22(4):283\u2013298. https:\/\/doi.org\/10.1038\/s41580-021-00328-y","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"2206_CR114","doi-asserted-by":"publisher","first-page":"E1130","DOI":"10.1210\/jc.2013-4048","volume":"99","author":"X Liu","year":"2014","unstructured":"Liu X, Qu S et al (2014) TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J Clin Endocrinol Metab 99(6):E1130\u20131136. https:\/\/doi.org\/10.1210\/jc.2013-4048","journal-title":"J Clin Endocrinol Metab"},{"key":"2206_CR108","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13046-015-0279-6","volume":"35","author":"L Liu","year":"2016","unstructured":"Liu L, Liu Y et al (2016) Synthetic bax-anti Bcl2 combination module actuated by super artificial hTERT promoter selectively inhibits malignant phenotypes of bladder cancer. J Exp Clin Cancer Res 35:3. https:\/\/doi.org\/10.1186\/s13046-015-0279-6","journal-title":"J Exp Clin Cancer Res"},{"key":"2206_CR112","doi-asserted-by":"publisher","unstructured":"Liu T, Yuan X et al (2016) Cancer-Specific Telomerase Reverse transcriptase (TERT) promoter mutations: Biological and Clinical implications. Genes 7(7). https:\/\/doi.org\/10.3390\/genes7070038","DOI":"10.3390\/genes7070038"},{"issue":"1","key":"2206_CR113","doi-asserted-by":"publisher","first-page":"179","DOI":"10.18632\/oncotarget.10162","volume":"8","author":"W Liu","year":"2017","unstructured":"Liu W, Yin Y et al (2017) Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC. Oncotarget 8(1):179\u2013190. https:\/\/doi.org\/10.18632\/oncotarget.10162","journal-title":"Oncotarget"},{"issue":"1","key":"2206_CR110","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/s41467-018-03033-1","volume":"9","author":"R Liu","year":"2018","unstructured":"Liu R, Zhang T et al (2018) Regulation of mutant TERT by BRAF V600E\/MAP kinase pathway through FOS\/GABP in human cancer. Nat Commun 9(1):579. https:\/\/doi.org\/10.1038\/s41467-018-03033-1","journal-title":"Nat Commun"},{"key":"2206_CR111","doi-asserted-by":"publisher","unstructured":"Liu S, Byrne BM et al (2023) Role of RPA Phosphorylation in the ATR-Dependent G2 cell cycle CheckpointGenes. Genes (Basel) 14(12):2205. https:\/\/doi.org\/10.3390\/genes14122205","DOI":"10.3390\/genes14122205"},{"issue":"1","key":"2206_CR109","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41419-024-06454-7","volume":"15","author":"M Liu","year":"2024","unstructured":"Liu M, Zhang Y et al (2024) The regulations of telomerase reverse transcriptase (TERT) in cancer. Cell Death Dis 15(1):90. https:\/\/doi.org\/10.1038\/s41419-024-06454-7","journal-title":"Cell Death Dis"},{"issue":"9","key":"2206_CR115","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.tibs.2013.07.001","volume":"38","author":"KC Low","year":"2013","unstructured":"Low KC, Tergaonkar V (2013) Telomerase: central regulator of all of the hallmarks of cancer. Trends Biochem Sci 38(9):426\u2013434. https:\/\/doi.org\/10.1016\/j.tibs.2013.07.001","journal-title":"Trends Biochem Sci"},{"issue":"9","key":"2206_CR116","doi-asserted-by":"publisher","first-page":"7181","DOI":"10.1007\/s11033-020-05551-y","volume":"47","author":"M Lulkiewicz","year":"2020","unstructured":"Lulkiewicz M, Bajsert J et al (2020) Telomere length: how the length makes a difference. Mol Biol Rep 47(9):7181\u20137188. https:\/\/doi.org\/10.1007\/s11033-020-05551-y","journal-title":"Mol Biol Rep"},{"issue":"2","key":"2206_CR117","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00428-015-1784-x","volume":"467","author":"E Macerola","year":"2015","unstructured":"Macerola E, Loggini B et al (2015) Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness. Virchows Arch 467(2):177\u2013184. https:\/\/doi.org\/10.1007\/s00428-015-1784-x","journal-title":"Virchows Arch"},{"issue":"18","key":"2206_CR118","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1158\/0008-5472.Can-22-0125","volume":"82","author":"SJ Macha","year":"2022","unstructured":"Macha SJ, Koneru B et al (2022) Alternative lengthening of telomeres in Cancer confers a vulnerability to reactivation of p53 function. Cancer Res 82(18):3345\u20133358. https:\/\/doi.org\/10.1158\/0008-5472.Can-22-0125","journal-title":"Cancer Res"},{"issue":"3","key":"2206_CR119","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nrm.2016.171","volume":"18","author":"J Maciejowski","year":"2017","unstructured":"Maciejowski J, de Lange T (2017) Telomeres in cancer: tumour suppression and genome instability. Nat Rev Mol Cell Biol 18(3):175\u2013186. https:\/\/doi.org\/10.1038\/nrm.2016.171","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2206_CR120","doi-asserted-by":"publisher","unstructured":"MacKenzie D Jr., Watters AK et al (2021) ALT positivity in human cancers: prevalence and clinical insights. Cancers 13(10). https:\/\/doi.org\/10.3390\/cancers13102384","DOI":"10.3390\/cancers13102384"},{"issue":"14","key":"2206_CR121","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1038\/onc.2015.246","volume":"35","author":"M Marchesini","year":"2016","unstructured":"Marchesini M, Matocci R et al (2016) PML is required for telomere stability in non-neoplastic human cells. Oncogene 35(14):1811\u20131821. https:\/\/doi.org\/10.1038\/onc.2015.246","journal-title":"Oncogene"},{"key":"2206_CR122","doi-asserted-by":"publisher","unstructured":"Mart\u00ednez P, Blasco MAJNRC (2011) Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins. Nat Rev Cancer 11(3):161\u2013176.https:\/\/doi.org\/10.1038\/nrc3025","DOI":"10.1038\/nrc3025"},{"issue":"5","key":"2206_CR123","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.cell.2015.01.044","volume":"160","author":"P Marzec","year":"2015","unstructured":"Marzec P, Armenise C et al (2015) Nuclear-receptor-mediated telomere insertion leads to genome instability in ALT cancers. Cell 160(5):913\u2013927. https:\/\/doi.org\/10.1016\/j.cell.2015.01.044","journal-title":"Cell"},{"key":"2206_CR124","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.coi.2017.07.004","volume":"47","author":"M Melssen","year":"2017","unstructured":"Melssen M, Slingluff CL Jr. (2017) Vaccines targeting helper T cells for cancer immunotherapy. Curr Opin Immunol 47:85\u201392. https:\/\/doi.org\/10.1016\/j.coi.2017.07.004","journal-title":"Curr Opin Immunol"},{"key":"2206_CR125","doi-asserted-by":"publisher","unstructured":"Mizukoshi E, Kaneko S (2019) Telomerase-targeted Cancer Immunotherapy. Int J Mol Sci 20(8). https:\/\/doi.org\/10.3390\/ijms20081823","DOI":"10.3390\/ijms20081823"},{"issue":"8","key":"2206_CR126","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1111\/cup.13691","volume":"47","author":"K Motaparthi","year":"2020","unstructured":"Motaparthi K, Kim J et al (2020) TERT and TERT promoter in melanocytic neoplasms: current concepts in pathogenesis, diagnosis, and prognosis. J Cutan Pathol 47(8):710\u2013719. https:\/\/doi.org\/10.1111\/cup.13691","journal-title":"J Cutan Pathol"},{"issue":"2","key":"2206_CR127","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nrm3505","volume":"14","author":"J Nandakumar","year":"2013","unstructured":"Nandakumar J, Cech TR (2013) Finding the end: recruitment of telomerase to telomeres. Nat Rev Mol Cell Biol 14(2):69\u201382. https:\/\/doi.org\/10.1038\/nrm3505","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2206_CR128","doi-asserted-by":"publisher","unstructured":"Negrini S, De Palma R et al (2020) Anti-cancer immunotherapies targeting telomerase. Cancers 12(8). https:\/\/doi.org\/10.3390\/cancers12082260","DOI":"10.3390\/cancers12082260"},{"issue":"4","key":"2206_CR129","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41571-024-00863-5","volume":"21","author":"NYL Ngoi","year":"2024","unstructured":"Ngoi NYL, Pili\u00e9 PG et al (2024) Targeting ATR in patients with cancer. Nat Reviews Clin Oncol 21(4):278\u2013293. https:\/\/doi.org\/10.1038\/s41571-024-00863-5","journal-title":"Nat Reviews Clin Oncol"},{"key":"2206_CR130","doi-asserted-by":"publisher","unstructured":"Nguyen DD, Chang S (2017) Development of Novel Therapeutic agents by Inhibition of oncogenic MicroRNAs. Int J Mol Sci 19(1). https:\/\/doi.org\/10.3390\/ijms19010065","DOI":"10.3390\/ijms19010065"},{"issue":"1","key":"2206_CR131","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.chembiol.2012.10.016","volume":"20","author":"GH Nguyen","year":"2013","unstructured":"Nguyen GH, Dexheimer TS et al (2013) A small molecule inhibitor of the BLM helicase modulates chromosome stability in human cells. Chem Biol 20(1):55\u201362. https:\/\/doi.org\/10.1016\/j.chembiol.2012.10.016","journal-title":"Chem Biol"},{"key":"2206_CR132","doi-asserted-by":"crossref","unstructured":"Nitta R, Go N et al (2012) Inhibition of telomerase with Imetelstat causes depletion of Cancer Stem CellsStem cells and Cancer Stem cells. Therapeutic Applications in Disease and Injury, vol 5. Springer, pp 13\u201324","DOI":"10.1007\/978-94-007-2900-1_2"},{"key":"2206_CR133","doi-asserted-by":"crossref","unstructured":"Niveta JS, Kumar MA et al (2022) Telomere attrition and inflammation: the chicken and the egg story. 23(1): 131","DOI":"10.1186\/s43042-022-00335-4"},{"issue":"2","key":"2206_CR134","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/nsmb.2754","volume":"21","author":"RJ O\u2019Sullivan","year":"2014","unstructured":"O\u2019Sullivan RJ, Arnoult N et al (2014) Rapid induction of alternative lengthening of telomeres by depletion of the histone chaperone ASF1. Nat Struct Mol Biol 21(2):167\u2013174. https:\/\/doi.org\/10.1038\/nsmb.2754","journal-title":"Nat Struct Mol Biol"},{"issue":"3","key":"2206_CR135","doi-asserted-by":"publisher","first-page":"883","DOI":"10.2741\/3652","volume":"15","author":"GG Oakley","year":"2010","unstructured":"Oakley GG, Patrick SM (2010) Replication protein A: directing traffic at the intersection of replication and repair. Front Bioscience (Landmark Edition) 15(3):883\u2013900. https:\/\/doi.org\/10.2741\/3652","journal-title":"Front Bioscience (Landmark Edition)"},{"issue":"1","key":"2206_CR136","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1038\/s41598-018-19300-6","volume":"8","author":"E Oh","year":"2018","unstructured":"Oh E, Hong J et al (2018) A hypoxia- and telomerase-responsive oncolytic adenovirus expressing secretable trimeric TRAIL triggers tumour-specific apoptosis and promotes viral dispersion in TRAIL-resistant glioblastoma. Sci Rep 8(1):1420. https:\/\/doi.org\/10.1038\/s41598-018-19300-6","journal-title":"Sci Rep"},{"key":"2206_CR137","doi-asserted-by":"publisher","first-page":"8201","DOI":"10.1038\/srep08201","volume":"5","author":"T Ohira","year":"2015","unstructured":"Ohira T, Naohiro S et al (2015) miR-19b regulates hTERT mRNA expression through targeting PITX1 mRNA in melanoma cells. Sci Rep 5:8201. https:\/\/doi.org\/10.1038\/srep08201","journal-title":"Sci Rep"},{"key":"2206_CR138","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.mad.2017.09.001","volume":"167","author":"D Oliva-Rico","year":"2017","unstructured":"Oliva-Rico D, Herrera LA (2017) Regulated expression of the lncRNA TERRA and its impact on telomere biology. Mech Ageing Dev 167:16\u201323. https:\/\/doi.org\/10.1016\/j.mad.2017.09.001","journal-title":"Mech Ageing Dev"},{"key":"2206_CR139","doi-asserted-by":"publisher","unstructured":"Olympios N, Gilard V et al (2021) TERT promoter alterations in Glioblastoma: a systematic review. Cancers 13(5). https:\/\/doi.org\/10.3390\/cancers13051147","DOI":"10.3390\/cancers13051147"},{"issue":"7","key":"2206_CR140","doi-asserted-by":"publisher","first-page":"111670","DOI":"10.1016\/j.celrep.2022.111670","volume":"41","author":"JA Oo","year":"2022","unstructured":"Oo JA, P\u00e1lfi K et al (2022) Long non-coding RNA PCAT19 safeguards DNA in quiescent endothelial cells by preventing uncontrolled phosphorylation of RPA2. Cell Rep 41(7):111670. https:\/\/doi.org\/10.1016\/j.celrep.2022.111670","journal-title":"Cell Rep"},{"issue":"29","key":"2206_CR141","doi-asserted-by":"publisher","first-page":"E5940","DOI":"10.1073\/pnas.1708065114","volume":"114","author":"X Pan","year":"2017","unstructured":"Pan X, Drosopoulos WC et al (2017) FANCM, BRCA1, and BLM cooperatively resolve the replication stress at the ALT telomeres. Proc Natl Acad Sci USA 114(29):E5940\u2013e5949. https:\/\/doi.org\/10.1073\/pnas.1708065114","journal-title":"Proc Natl Acad Sci USA"},{"issue":"13","key":"2206_CR142","doi-asserted-by":"publisher","first-page":"5831","DOI":"10.1002\/cam4.2467","volume":"8","author":"F Panebianco","year":"2019","unstructured":"Panebianco F, Nikitski AV et al (2019) Spectrum of TERT promoter mutations and mechanisms of activation in thyroid cancer. Cancer Med 8(13):5831\u20135839. https:\/\/doi.org\/10.1002\/cam4.2467","journal-title":"Cancer Med"},{"issue":"10","key":"2206_CR143","doi-asserted-by":"publisher","first-page":"7493","DOI":"10.18632\/oncotarget.2115","volume":"6","author":"A Pezzolo","year":"2015","unstructured":"Pezzolo A, Pistorio A et al (2015) Intratumoral diversity of telomere length in individual neuroblastoma tumors. Oncotarget 6(10):7493\u20137503. https:\/\/doi.org\/10.18632\/oncotarget.2115","journal-title":"Oncotarget"},{"issue":"5","key":"2206_CR144","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1111\/j.1742-4658.2009.07464.x","volume":"277","author":"AT Phan","year":"2010","unstructured":"Phan AT (2010) Human telomeric G-quadruplex: structures of DNA and RNA sequences. FEBS J 277(5):1107\u20131117. https:\/\/doi.org\/10.1111\/j.1742-4658.2009.07464.x","journal-title":"FEBS J"},{"issue":"5","key":"2206_CR145","doi-asserted-by":"publisher","first-page":"761","DOI":"10.18632\/oncotarget.1047","volume":"4","author":"RT Pitman","year":"2013","unstructured":"Pitman RT, Wojdyla L et al (2013) Mechanism of DNA damage responses induced by exposure to an oligonucleotide homologous to the telomere overhang in melanoma. Oncotarget 4(5):761\u2013771. https:\/\/doi.org\/10.18632\/oncotarget.1047","journal-title":"Oncotarget"},{"issue":"17","key":"2206_CR146","doi-asserted-by":"publisher","first-page":"14289","DOI":"10.1074\/jbc.M112.353201","volume":"287","author":"C Punchihewa","year":"2012","unstructured":"Punchihewa C, Inoue A et al (2012) Identification of small molecule proliferating cell nuclear antigen (PCNA) inhibitor that disrupts interactions with PIP-box proteins and inhibits DNA replication. J Biol Chem 287(17):14289\u201314300. https:\/\/doi.org\/10.1074\/jbc.M112.353201","journal-title":"J Biol Chem"},{"issue":"6","key":"2206_CR147","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s12032-022-01702-2","volume":"39","author":"S Quazi","year":"2022","unstructured":"Quazi S (2022) Telomerase gene therapy: a remission toward cancer. Med Oncol 39(6):105. https:\/\/doi.org\/10.1007\/s12032-022-01702-2","journal-title":"Med Oncol"},{"issue":"5","key":"2206_CR148","doi-asserted-by":"publisher","first-page":"e29665","DOI":"10.1002\/jmv.29665","volume":"96","author":"S Rasouli","year":"2024","unstructured":"Rasouli S, Dakic A et al (2024) Noncanonical functions of telomerase and telomeres in viruses-associated cancer. J Med Virol 96(5):e29665. https:\/\/doi.org\/10.1002\/jmv.29665","journal-title":"J Med Virol"},{"key":"2206_CR149","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S1359-6349(10)72095-4","volume":"8","author":"MJ Ratain","year":"2010","unstructured":"Ratain MJ, Kelsey S et al (2010) 388 Imetelstat sodium (GRN163L), a telomerase inhibitor: tolerability, pharmacokinetics and pharmacodynamic activity using an intermittent once every four weeks dosing schedule in patients with advanced solid tumors. Ejc Supplements - EJC SUPPL 8:123\u2013123. https:\/\/doi.org\/10.1016\/S1359-6349(10)72095-4","journal-title":"Ejc Supplements - EJC SUPPL"},{"key":"2206_CR150","doi-asserted-by":"publisher","unstructured":"Recagni M, Bidzinska J et al (2020) The role of alternative lengthening of telomeres mechanism in Cancer: translational and therapeutic implications. Cancers 12(4). https:\/\/doi.org\/10.3390\/cancers12040949","DOI":"10.3390\/cancers12040949"},{"issue":"41","key":"2206_CR151","doi-asserted-by":"publisher","first-page":"6361","DOI":"10.2174\/1381612820666140630101047","volume":"20","author":"RR Reddel","year":"2014","unstructured":"Reddel RR (2014) Telomere maintenance mechanisms in cancer: clinical implications. Curr Pharm Des 20(41):6361\u20136374. https:\/\/doi.org\/10.2174\/1381612820666140630101047","journal-title":"Curr Pharm Des"},{"issue":"6","key":"2206_CR152","doi-asserted-by":"publisher","first-page":"433","DOI":"10.2174\/1568026620666200102104930","volume":"20","author":"N Relitti","year":"2020","unstructured":"Relitti N, Saraswati AP et al (2020) Telomerase-based Cancer therapeutics: a review on their clinical trials. Curr Top Med Chem 20(6):433\u2013457. https:\/\/doi.org\/10.2174\/1568026620666200102104930","journal-title":"Curr Top Med Chem"},{"key":"2206_CR153","doi-asserted-by":"publisher","unstructured":"Rhim J, Baek W et al (2022) From Molecular mechanisms to therapeutics: understanding MicroRNA-21 in Cancer. Cells 11(18). https:\/\/doi.org\/10.3390\/cells11182791","DOI":"10.3390\/cells11182791"},{"issue":"7","key":"2206_CR154","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/s41580-020-0234-z","volume":"21","author":"CM Roake","year":"2020","unstructured":"Roake CM, Artandi SE (2020) Regulation of human telomerase in homeostasis and disease. Nat Rev Mol Cell Biol 21(7):384\u2013397. https:\/\/doi.org\/10.1038\/s41580-020-0234-z","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"2206_CR155","doi-asserted-by":"publisher","first-page":"7086","DOI":"10.1038\/s41467-023-42831-0","volume":"14","author":"I Rosso","year":"2023","unstructured":"Rosso I, Jones-Weinert C et al (2023) Alternative lengthening of telomeres (ALT) cells viability is dependent on C-rich telomeric RNAs. Nat Commun 14(1):7086. https:\/\/doi.org\/10.1038\/s41467-023-42831-0","journal-title":"Nat Commun"},{"key":"2206_CR156","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/978-3-642-01222-8_16","volume":"184","author":"A R\u00f6th","year":"2010","unstructured":"R\u00f6th A, Harley CB et al (2010a) Imetelstat (GRN163L)--telomerase-based cancer therapy. Recent Results Cancer Res 184:221\u2013234. https:\/\/doi.org\/10.1007\/978-3-642-01222-8_16","journal-title":"Recent Results Cancer Res"},{"key":"2206_CR157","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/978-3-642-01222-8_16","volume-title":"Small molecules in Oncology","author":"A R\u00f6th","year":"2010","unstructured":"R\u00f6th A, Harley CB et al (2010b) Imetelstat (GRN163L) - telomerase-based Cancer Therapy. In: Martens UM (ed) Small molecules in Oncology. Springer Berlin Heidelberg, Berlin, Heidelberg, pp 221\u2013234"},{"issue":"8","key":"2206_CR158","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.1007\/s11033-013-2600-9","volume":"40","author":"B Rubis","year":"2013","unstructured":"Rubis B, Holysz H et al (2013) Telomerase downregulation induces proapoptotic genes expression and initializes breast cancer cells apoptosis followed by DNA fragmentation in a cell type dependent manner. Mol Biol Rep 40(8):4995\u20135004. https:\/\/doi.org\/10.1007\/s11033-013-2600-9","journal-title":"Mol Biol Rep"},{"issue":"4","key":"2206_CR159","doi-asserted-by":"publisher","first-page":"431","DOI":"10.4067\/s0716-97602013000400014","volume":"46","author":"F Salazar-Onfray","year":"2013","unstructured":"Salazar-Onfray F, Pereda C et al (2013) TAPCells, the Chilean dendritic cell vaccine against melanoma and prostate cancer. Biol Res 46(4):431\u2013440. https:\/\/doi.org\/10.4067\/s0716-97602013000400014","journal-title":"Biol Res"},{"key":"2206_CR160","doi-asserted-by":"publisher","first-page":"100323","DOI":"10.1016\/j.ctarc.2021.100323","volume":"27","author":"A Salimi-Jeda","year":"2021","unstructured":"Salimi-Jeda A, Badrzadeh F et al (2021) The role of telomerase and viruses interaction in cancer development, and telomerase-dependent therapeutic approaches. Cancer Treat Res Commun 27:100323. https:\/\/doi.org\/10.1016\/j.ctarc.2021.100323","journal-title":"Cancer Treat Res Commun"},{"issue":"3","key":"2206_CR161","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s11060-016-2189-7","volume":"129","author":"R Salloum","year":"2016","unstructured":"Salloum R, Hummel TR et al (2016) A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study. J Neurooncol 129(3):443\u2013451. https:\/\/doi.org\/10.1007\/s11060-016-2189-7","journal-title":"J Neurooncol"},{"issue":"1","key":"2206_CR162","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1089\/oli.2010.0259","volume":"21","author":"S Sarkar","year":"2011","unstructured":"Sarkar S, Faller DV (2011) T-oligos inhibit growth and induce apoptosis in human ovarian cancer cells. Oligonucleotides 21(1):47\u201353. https:\/\/doi.org\/10.1089\/oli.2010.0259","journal-title":"Oligonucleotides"},{"issue":"11","key":"2206_CR163","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1101\/gad.263863.115","volume":"29","author":"JC Schmidt","year":"2015","unstructured":"Schmidt JC, Cech TR (2015) Human telomerase: biogenesis, trafficking, recruitment, and activation. Genes Dev 29(11):1095\u20131105. https:\/\/doi.org\/10.1101\/gad.263863.115","journal-title":"Genes Dev"},{"key":"2206_CR164","doi-asserted-by":"publisher","unstructured":"Schrank Z, Khan N et al (2018) Oligonucleotides targeting telomeres and telomerase in Cancer. Molecules 23(9). https:\/\/doi.org\/10.3390\/molecules23092267","DOI":"10.3390\/molecules23092267"},{"issue":"1","key":"2206_CR165","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.cell.2009.06.021","volume":"138","author":"A Sfeir","year":"2009","unstructured":"Sfeir A, Kosiyatrakul ST et al (2009) Mammalian telomeres resemble fragile sites and require TRF1 for efficient replication. Cell 138(1):90\u2013103. https:\/\/doi.org\/10.1016\/j.cell.2009.06.021","journal-title":"Cell"},{"issue":"7","key":"2206_CR166","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/leu.2008.81","volume":"22","author":"MA Shammas","year":"2008","unstructured":"Shammas MA, Koley H et al (2008) Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. Leukemia 22(7):1410\u20131418. https:\/\/doi.org\/10.1038\/leu.2008.81","journal-title":"Leukemia"},{"issue":"5","key":"2206_CR167","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41576-019-0099-1","volume":"20","author":"JW Shay","year":"2019","unstructured":"Shay JW, Wright WE (2019) Telomeres and telomerase: three decades of progress. Nat Rev Genet 20(5):299\u2013309. https:\/\/doi.org\/10.1038\/s41576-019-0099-1","journal-title":"Nat Rev Genet"},{"key":"2206_CR168","doi-asserted-by":"publisher","unstructured":"Shay JWJCd (2016) Role of telomeres and telomerase in aging and cancer. Cancer Discov 6(6):584\u2013593. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0062","DOI":"10.1158\/2159-8290.CD-16-0062"},{"key":"2206_CR169","doi-asserted-by":"publisher","unstructured":"Simeonova I, Almouzni G (2024) Histone H3 Variants in the Multiverse of Cancer. Annual Review of Cancer Biology 8(Volume 8, 2024): 453\u2013474. https:\/\/doi.org\/10.1146\/annurev-cancerbio-062722-021823","DOI":"10.1146\/annurev-cancerbio-062722-021823"},{"issue":"1","key":"2206_CR170","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/neuonc\/nou158","volume":"17","author":"M Simon","year":"2015","unstructured":"Simon M, Hosen I et al (2015) TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. Neuro Oncol 17(1):45\u201352. https:\/\/doi.org\/10.1093\/neuonc\/nou158","journal-title":"Neuro Oncol"},{"issue":"1","key":"2206_CR171","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00018-019-03369-x","volume":"77","author":"EM Smith","year":"2020","unstructured":"Smith EM, Pendlebury DF et al (2020) Structural biology of telomeres and telomerase. Cell Mol Life Sci 77(1):61\u201379. https:\/\/doi.org\/10.1007\/s00018-019-03369-x","journal-title":"Cell Mol Life Sci"},{"key":"2206_CR172","doi-asserted-by":"publisher","unstructured":"Sohn EJ, Goralsky JA et al (2023) The Molecular mechanisms and therapeutic prospects of alternative lengthening of telomeres (ALT). Cancers 15(7). https:\/\/doi.org\/10.3390\/cancers15071945","DOI":"10.3390\/cancers15071945"},{"key":"2206_CR173","doi-asserted-by":"publisher","unstructured":"Sommer A, Royle NJ (2020) ALT: a multi-faceted Phenomenon. Genes 11(2). https:\/\/doi.org\/10.3390\/genes11020133","DOI":"10.3390\/genes11020133"},{"issue":"3","key":"2206_CR174","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.3892\/ijo.2014.2496","volume":"45","author":"C Staff","year":"2014","unstructured":"Staff C, Mozaffari F et al (2014) Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients. Int J Oncol 45(3):1293\u20131303. https:\/\/doi.org\/10.3892\/ijo.2014.2496","journal-title":"Int J Oncol"},{"issue":"8","key":"2206_CR175","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.3390\/cancers12082207","volume":"12","author":"J-Y Sung","year":"2020","unstructured":"Sung J-Y, Lim H-W et al (2020) Pan-cancer Analysis of Alternative Lengthening of Telomere Activity. Cancers 12(8):2207","journal-title":"Cancers"},{"issue":"9","key":"2206_CR176","doi-asserted-by":"publisher","first-page":"e6919","DOI":"10.1371\/journal.pone.0006919","volume":"4","author":"N Temime-Smaali","year":"2009","unstructured":"Temime-Smaali N, Guittat L et al (2009) The G-quadruplex ligand telomestatin impairs binding of topoisomerase IIIalpha to G-quadruplex-forming oligonucleotides and uncaps telomeres in ALT cells. PLoS ONE 4(9):e6919. https:\/\/doi.org\/10.1371\/journal.pone.0006919","journal-title":"PLoS ONE"},{"issue":"3","key":"2206_CR177","doi-asserted-by":"publisher","first-page":"e1083670","DOI":"10.1080\/2162402x.2015.1083670","volume":"5","author":"J Thalmensi","year":"2016","unstructured":"Thalmensi J, Pliquet E et al (2016) Anticancer DNA vaccine based on human telomerase reverse transcriptase generates a strong and specific T cell immune response. Oncoimmunology 5(3):e1083670. https:\/\/doi.org\/10.1080\/2162402x.2015.1083670","journal-title":"Oncoimmunology"},{"issue":"23","key":"2206_CR178","doi-asserted-by":"publisher","first-page":"6578","DOI":"10.1158\/1078-0432.Ccr-13-1117","volume":"19","author":"PA Thompson","year":"2013","unstructured":"Thompson PA, Drissi R, Oncology Group Phase I Consortium Study (ADVL1112) (2013) A phase I trial of imetelstat in children with refractory or recurrent solid tumors: a children\u2019s. Clin cancer Research: Official J Am Association Cancer Res 19(23):6578\u20136584. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-13-1117","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"issue":"2","key":"2206_CR179","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s12015-010-9124-7","volume":"6","author":"Z Tokcaer-Keskin","year":"2010","unstructured":"Tokcaer-Keskin Z, Dikmen ZG et al (2010) The effect of telomerase template antagonist GRN163L on bone-marrow-derived rat mesenchymal stem cells is reversible and associated with altered expression of cyclin d1, cdk4 and cdk6. Stem Cell Rev Rep 6(2):224\u2013233. https:\/\/doi.org\/10.1007\/s12015-010-9124-7","journal-title":"Stem Cell Rev Rep"},{"key":"2206_CR180","doi-asserted-by":"publisher","first-page":"102901","DOI":"10.1016\/j.dnarep.2020.102901","volume":"94","author":"\u013d Tom\u00e1\u0161ka","year":"2020","unstructured":"Tom\u00e1\u0161ka \u013d, Cesare AJ et al (2020) Twenty years of t-loops: a case study for the importance of collaboration in molecular biology. DNA Repair 94:102901. https:\/\/doi.org\/10.1016\/j.dnarep.2020.102901","journal-title":"DNA Repair"},{"key":"2206_CR182","doi-asserted-by":"publisher","unstructured":"Tornesello ML, Cerasuolo A et al (2022) The Molecular Interplay between Human oncoviruses and Telomerase in Cancer Development. Cancers 14(21). https:\/\/doi.org\/10.3390\/cancers14215257","DOI":"10.3390\/cancers14215257"},{"key":"2206_CR181","doi-asserted-by":"publisher","first-page":"1286683","DOI":"10.3389\/fcell.2023.1286683","volume":"11","author":"ML Tornesello","year":"2023","unstructured":"Tornesello ML, Cerasuolo A et al (2023) Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations. Front cell Dev Biology 11:1286683. https:\/\/doi.org\/10.3389\/fcell.2023.1286683","journal-title":"Front cell Dev Biology"},{"issue":"10","key":"2206_CR184","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1210\/en.2019-00315","volume":"160","author":"T Trybek","year":"2019","unstructured":"Trybek T, Walczyk A et al (2019) Impact of BRAF V600E and TERT promoter mutations on response to therapy in papillary thyroid Cancer. Endocrinology 160(10):2328\u20132338. https:\/\/doi.org\/10.1210\/en.2019\u201300315","journal-title":"Endocrinology"},{"issue":"2","key":"2206_CR183","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.3892\/ol.2020.11659","volume":"20","author":"T Trybek","year":"2020","unstructured":"Trybek T, Kowalik A et al (2020) Telomeres and telomerase in oncogenesis. Oncol Lett 20(2):1015\u20131027. https:\/\/doi.org\/10.3892\/ol.2020.11659","journal-title":"Oncol Lett"},{"key":"2206_CR185","doi-asserted-by":"crossref","unstructured":"Tsubouchi H (2023) The Hop2-Mnd1 Complex and Its Regulation of Homologous RecombinationBiomolecules","DOI":"10.3390\/biom13040662"},{"key":"2206_CR186","doi-asserted-by":"publisher","unstructured":"Valenzuela M, Amato R et al (2021) The multiple facets of ATRX protein. Cancers 13(9). https:\/\/doi.org\/10.3390\/cancers13092211","DOI":"10.3390\/cancers13092211"},{"issue":"10","key":"2206_CR187","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1136\/bjophthalmol-2020-317405","volume":"105","author":"JA van Ipenburg","year":"2021","unstructured":"van Ipenburg JA, Naus NC et al (2021) Prognostic value of TERT promoter mutations in conjunctival melanomas in addition to clinicopathological features. Br J Ophthalmol 105(10):1454\u20131461. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-317405","journal-title":"Br J Ophthalmol"},{"key":"2206_CR188","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ebiom.2017.03.027","volume":"21","author":"S Victorelli","year":"2017","unstructured":"Victorelli S, Passos JF (2017) Telomeres and cell senescence -. Size Matters Not EBioMedicine 21:14\u201320. https:\/\/doi.org\/10.1016\/j.ebiom.2017.03.027","journal-title":"Size Matters Not EBioMedicine"},{"issue":"1","key":"2206_CR189","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1186\/s12885-020-07364-5","volume":"20","author":"HG Vuong","year":"2020","unstructured":"Vuong HG, Nguyen TQ et al (2020) The interaction between TERT promoter mutation and MGMT promoter methylation on overall survival of glioma patients: a meta-analysis. BMC Cancer 20(1):897. https:\/\/doi.org\/10.1186\/s12885-020-07364-5","journal-title":"BMC Cancer"},{"issue":"9","key":"2206_CR192","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/j.1755-5949.2012.00349.x","volume":"18","author":"YY Wang","year":"2012","unstructured":"Wang YY, Sun G et al (2012) MiR-21 modulates hTERT through a STAT3-dependent manner on glioblastoma cell growth. CNS Neurosci Ther 18(9):722\u2013728. https:\/\/doi.org\/10.1111\/j.1755-5949.2012.00349.x","journal-title":"CNS Neurosci Ther"},{"issue":"6","key":"2206_CR190","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.3892\/mmr.2017.6549","volume":"15","author":"H Wang","year":"2017","unstructured":"Wang H, Zhou J et al (2017) Azidothymidine inhibits cell growth and telomerase activity and induces DNA damage in human esophageal cancer. Mol Med Rep 15(6):4055\u20134060. https:\/\/doi.org\/10.3892\/mmr.2017.6549","journal-title":"Mol Med Rep"},{"key":"2206_CR193","doi-asserted-by":"publisher","unstructured":"Wang Z, Deng Z et al (2017) The telomeric response to viral infection. Viruses 9(8). https:\/\/doi.org\/10.3390\/v9080218","DOI":"10.3390\/v9080218"},{"issue":"18","key":"2206_CR191","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1182\/bloodadvances.2018022012","volume":"2","author":"X Wang","year":"2018","unstructured":"Wang X, Hu CS et al (2018) Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells. Blood Adv 2(18):2378\u20132388. https:\/\/doi.org\/10.1182\/bloodadvances.2018022012","journal-title":"Blood Adv"},{"issue":"4","key":"2206_CR194","doi-asserted-by":"publisher","first-page":"769","DOI":"10.3892\/or.2011.1371","volume":"26","author":"M Watanabe","year":"2011","unstructured":"Watanabe M, Ueki H et al (2011) Advanced two-step transcriptional amplification as a novel method for cancer-specific gene expression and imaging. Oncol Rep 26(4):769\u2013775. https:\/\/doi.org\/10.3892\/or.2011.1371","journal-title":"Oncol Rep"},{"key":"2206_CR195","doi-asserted-by":"publisher","unstructured":"Webb CJ, Wu Y et al (2013) DNA repair at telomeres: keeping the ends intact. Cold Spring Harb Perspect Biol 5(6). https:\/\/doi.org\/10.1101\/cshperspect.a012666","DOI":"10.1101\/cshperspect.a012666"},{"issue":"2","key":"2206_CR196","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.bbrc.2014.03.013","volume":"446","author":"L Wojdyla","year":"2014","unstructured":"Wojdyla L, Stone AL et al (2014) T-oligo as an anticancer agent in colorectal cancer. Biochem Biophys Res Commun 446(2):596\u2013601. https:\/\/doi.org\/10.1016\/j.bbrc.2014.03.013","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"2206_CR197","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1007\/s11033-010-0439-x","volume":"38","author":"A Wojtyla","year":"2011","unstructured":"Wojtyla A, Gladych M et al (2011) Human telomerase activity regulation. Mol Biol Rep 38(5):3339\u20133349. https:\/\/doi.org\/10.1007\/s11033-010-0439-x","journal-title":"Mol Biol Rep"},{"key":"2206_CR198","doi-asserted-by":"publisher","unstructured":"Wong MS, Wright WE et al (2014) Alternative splicing regulation of telomerase: a new paradigm? Trends in genetics: TIG. 30(10):430\u2013438. https:\/\/doi.org\/10.1016\/j.tig.2014.07.006","DOI":"10.1016\/j.tig.2014.07.006"},{"issue":"8","key":"2206_CR200","doi-asserted-by":"publisher","first-page":"13600","DOI":"10.18632\/oncotarget.14618","volume":"8","author":"X Wu","year":"2017","unstructured":"Wu X, Zhang J et al (2017) Telomerase antagonist imetelstat increases radiation sensitivity in esophageal squamous cell carcinoma. Oncotarget 8(8):13600\u201313619. https:\/\/doi.org\/10.18632\/oncotarget.14618","journal-title":"Oncotarget"},{"key":"2206_CR199","doi-asserted-by":"publisher","unstructured":"Wu G, Chen L et al (2019) Molecular Recognition of the hybrid-type G-Quadruplexes in human telomeres. Molecules 24(8). https:\/\/doi.org\/10.3390\/molecules24081578","DOI":"10.3390\/molecules24081578"},{"key":"2206_CR201","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s13059-015-0791-1","volume":"16","author":"L Xi","year":"2015","unstructured":"Xi L, Schmidt JC et al (2015) A novel two-step genome editing strategy with CRISPR-Cas9 provides new insights into telomerase action and TERT gene expression. Genome Biol 16:231. https:\/\/doi.org\/10.1186\/s13059-015-0791-1","journal-title":"Genome Biol"},{"issue":"2","key":"2206_CR202","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/cncr.26289","volume":"118","author":"J Xiong","year":"2012","unstructured":"Xiong J, Sun WJ et al (2012) Novel, chimeric, cancer-specific, and radiation-inducible gene promoters for suicide gene therapy of cancer. Cancer 118(2):536\u2013548. https:\/\/doi.org\/10.1002\/cncr.26289","journal-title":"Cancer"},{"issue":"6","key":"2206_CR205","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/genes7060022","volume":"7","author":"Y Xu","year":"2016","unstructured":"Xu Y, Goldkorn A (2016) Telomere and Telomerase therapeutics in Cancer. Genes 7(6):22","journal-title":"Genes"},{"issue":"1","key":"2206_CR203","doi-asserted-by":"publisher","first-page":"14432","DOI":"10.1038\/ncomms14432","volume":"8","author":"H Xu","year":"2017","unstructured":"Xu H, Di Antonio M et al (2017) CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1\/2 deficient tumours. Nat Commun 8(1):14432. https:\/\/doi.org\/10.1038\/ncomms14432","journal-title":"Nat Commun"},{"issue":"1","key":"2206_CR204","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1038\/s41467-024-46509-z","volume":"15","author":"M Xu","year":"2024","unstructured":"Xu M, Senanayaka D et al (2024) TERRA-LSD1 phase separation promotes R-loop formation for telomere maintenance in ALT cancer cells. Nat Commun 15(1):2165. https:\/\/doi.org\/10.1038\/s41467-024-46509-z","journal-title":"Nat Commun"},{"issue":"3","key":"2206_CR206","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1158\/2326-6066.Cir-13-0001","volume":"1","author":"J Yan","year":"2013","unstructured":"Yan J, Pankhong P et al (2013) Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity. Cancer Immunol Res 1(3):179\u2013189. https:\/\/doi.org\/10.1158\/2326-6066.Cir-13-0001","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2206_CR207","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s13578-023-01181-6","volume":"13","author":"S Yan","year":"2023","unstructured":"Yan S, Lin S et al (2023) Regulation of telomerase towards tumor therapy. Cell Biosci 13(1):228. https:\/\/doi.org\/10.1186\/s13578-023-01181-6","journal-title":"Cell Biosci"},{"issue":"1","key":"2206_CR208","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s13105-015-0380-5","volume":"71","author":"Y Yang","year":"2015","unstructured":"Yang Y, Yang JJ et al (2015) MicroRNA-21 controls hTERT via PTEN in human colorectal cancer cell proliferation. J Physiol Biochem 71(1):59\u201368. https:\/\/doi.org\/10.1007\/s13105-015-0380-5","journal-title":"J Physiol Biochem"},{"issue":"1","key":"2206_CR209","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40164-022-00257-2","volume":"11","author":"J Yu","year":"2022","unstructured":"Yu J, Sun H et al (2022) Research progress on dendritic cell vaccines in cancer immunotherapy. Exp Hematol Oncol 11(1):3. https:\/\/doi.org\/10.1186\/s40164-022-00257-2","journal-title":"Exp Hematol Oncol"},{"key":"2206_CR211","doi-asserted-by":"publisher","unstructured":"Yuan X, Xu D (2019) Telomerase Reverse Transcriptase (TERT) in Action: cross-talking with epigenetics. Int J Mol Sci 20(13). https:\/\/doi.org\/10.3390\/ijms20133338","DOI":"10.3390\/ijms20133338"},{"issue":"34","key":"2206_CR210","doi-asserted-by":"publisher","first-page":"6172","DOI":"10.1038\/s41388-019-0872-9","volume":"38","author":"X Yuan","year":"2019","unstructured":"Yuan X, Larsson C et al (2019) Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players. Oncogene 38(34):6172\u20136183. https:\/\/doi.org\/10.1038\/s41388-019-0872-9","journal-title":"Oncogene"},{"issue":"2","key":"2206_CR212","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s00775-022-01973-0","volume":"28","author":"J Zegers","year":"2023","unstructured":"Zegers J, Peters M et al (2023) DNA G-quadruplex-stabilizing metal complexes as anticancer drugs. J Biol Inorg Chem 28(2):117\u2013138. https:\/\/doi.org\/10.1007\/s00775-022-01973-0","journal-title":"J Biol Inorg Chem"},{"issue":"1","key":"2206_CR213","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40364-024-00581-1","volume":"12","author":"M Zeng","year":"2024","unstructured":"Zeng M, Zhang W et al (2024) Harnessing adenovirus in cancer immunotherapy: evoking cellular immunity and targeting delivery in cell-specific manner. Biomark Res 12(1):36. https:\/\/doi.org\/10.1186\/s40364-024-00581-1","journal-title":"Biomark Res"},{"issue":"2","key":"2206_CR214","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.canlet.2015.01.044","volume":"360","author":"D Zhang","year":"2015","unstructured":"Zhang D, Xiao YF et al (2015) miR-1182 attenuates gastric cancer proliferation and metastasis by targeting the open reading frame of hTERT. Cancer Lett 360(2):151\u2013159. https:\/\/doi.org\/10.1016\/j.canlet.2015.01.044","journal-title":"Cancer Lett"},{"issue":"18","key":"2206_CR216","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1091\/mbc.E19-10-0589","volume":"31","author":"H Zhang","year":"2020","unstructured":"Zhang H, Zhao R et al (2020) Nuclear body phase separation drives telomere clustering in ALT cancer cells. Mol Biol Cell 31(18):2048\u20132056. https:\/\/doi.org\/10.1091\/mbc.E19-10-0589","journal-title":"Mol Biol Cell"},{"issue":"5","key":"2206_CR217","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.molcel.2020.12.030","volume":"81","author":"J-M Zhang","year":"2021","unstructured":"Zhang J-M, Genois M-M et al (2021) Alternative lengthening of telomeres is a self-perpetuating process in ALT-associated PML bodies. Mol Cell 81(5):1027\u20131042e1024. https:\/\/doi.org\/10.1016\/j.molcel.2020.12.030","journal-title":"Mol Cell"},{"issue":"2","key":"2206_CR220","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/ijc.34007","volume":"151","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Luo S et al (2022) Telomere maintenance mechanism dysregulation serves as an early predictor of adjuvant therapy response and a potential therapeutic target in human cancers. Int J Cancer 151(2):313\u2013327. https:\/\/doi.org\/10.1002\/ijc.34007","journal-title":"Int J Cancer"},{"issue":"1","key":"2206_CR215","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41392-023-01579-1","volume":"8","author":"G Zhang","year":"2023","unstructured":"Zhang G, Tang T et al (2023) mRNA vaccines in disease prevention and treatment. Signal Transduct Target Therapy 8(1):365. https:\/\/doi.org\/10.1038\/s41392-023-01579-1","journal-title":"Signal Transduct Target Therapy"},{"key":"2206_CR219","doi-asserted-by":"crossref","unstructured":"Zhang Y, Hou K et al (2023) The altered functions of Shelterin Components in ALT CellsInternational. Journal of Molecular Sciences","DOI":"10.3390\/ijms242316830"},{"key":"2206_CR218","doi-asserted-by":"crossref","unstructured":"Zhang J, Chen B et al (2023) A comprehensive review of small interfering RNAs (siRNAs): mechanism, therapeutic targets, and delivery strategies for cancer therapy. Int J Nanomed 13(18):7605\u20137635","DOI":"10.2147\/IJN.S436038"},{"key":"2206_CR221","doi-asserted-by":"publisher","unstructured":"Zhao S, Wang F et al (2019) Alternative lengthening of telomeres (ALT) in tumors and pluripotent stem cells. Genes 10(12). https:\/\/doi.org\/10.3390\/genes10121030","DOI":"10.3390\/genes10121030"},{"issue":"5","key":"2206_CR223","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.3892\/ol.2016.5038","volume":"12","author":"N Zhou","year":"2016","unstructured":"Zhou N, Fei D et al (2016) MicroRNA-138 inhibits proliferation, migration and invasion through targeting hTERT in cervical cancer. Oncol Lett 12(5):3633\u20133639. https:\/\/doi.org\/10.3892\/ol.2016.5038","journal-title":"Oncol Lett"},{"issue":"1","key":"2206_CR222","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3892\/ol.2020.12277","volume":"21","author":"C Zhou","year":"2021","unstructured":"Zhou C, Ma J et al (2021) TERT promoter regulating melittin expression induces apoptosis and G(0)\/G(1) cell cycle arrest in esophageal carcinoma cells. Oncol Lett 21(1):16. https:\/\/doi.org\/10.3892\/ol.2020.12277","journal-title":"Oncol Lett"},{"issue":"31","key":"2206_CR224","doi-asserted-by":"publisher","first-page":"e2201662119","DOI":"10.1073\/pnas.2201662119","volume":"119","author":"JC Zinder","year":"2022","unstructured":"Zinder JC, Olinares PDB et al (2022) Shelterin is a dimeric complex with extensive structural heterogeneity. Proc Natl Acad Sci USA 119(31):e2201662119. https:\/\/doi.org\/10.1073\/pnas.2201662119","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Molecular Genetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00438-024-02206-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00438-024-02206-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00438-024-02206-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T03:03:18Z","timestamp":1733454198000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00438-024-02206-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":224,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2206"],"URL":"https:\/\/doi.org\/10.1007\/s00438-024-02206-6","relation":{},"ISSN":["1617-4615","1617-4623"],"issn-type":[{"value":"1617-4615","type":"print"},{"value":"1617-4623","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,6]]},"assertion":[{"value":"26 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors claim an absence of financial interests and an absence of conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}